Concepedia

Author

Michael Leonardi

GlaxoSmithKline (United States)

Also Known As

M. Leonardi, Michael L. Leonardi, Michael Leonardi

15

Publications

212

Citations

8

H-Index

8

Concepts

All Affiliations

GlaxoSmithKline (United States)GlaxoSmithKline (Belgium)Kaiser PermanenteMarshall UniversityKaiser Permanente Oakland Medical Center
ML

About

Michael Leonardi is an author at GlaxoSmithKline (United States) specializing in craniofacial surgery, neuropathology, and craniofacial anomalies.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

62

2

Pathology

1

1

62

3

Craniofacial Surgery

1

1

62

4

Neuropathology

1

1

62

5

Congenital Disorders

1

1

62

Michael Leonardi

×

7

Publications

185

Citations

7

H-Index

YearCitations

Ritscher-Schinzel cranio-cerebello-cardiac (3C) syndrome: Report of four new cases and review

Michael Leonardi, G. Shashidhar Pai, Beth Wilkes,

American Journal of Medical Genetics

2001

62

Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial

Varsha Jain, Joseph B. Domachowske, Long Wang,

Journal of the Pediatric Infectious Diseases Society

2016

34

Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in Infants

Gary S. Marshall, Gregory L. Adams, Michael Leonardi,

PEDIATRICS

2015

31

Immunogenicity and Safety of Two Tetravalent (Measles, Mumps, Rubella, Varicella) Vaccines Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children Twelve to Fourteen Months of Age

Mark M. Blatter, Nicola P. Klein, Julie S. Shepard,

The Pediatric Infectious Disease Journal

2012

24

Immunogenicity and Safety of MMRV and PCV-7 Administered Concomitantly in Healthy Children

Michael Leonardi, Kenneth Bromberg, Roger Baxter,

PEDIATRICS

2011

12

Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™

Michael Leonardi, Thomas Latiolais, Kwabena Sarpong,

Vaccine

2014

11

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

Andrea A. Berry, Remon Abu‐Elyazeed, Clemente Díaz-Pérez,

Human Vaccines & Immunotherapeutics

2017

11

Page 1